HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.